Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Correction: First-in-human pha...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Bibliographic Details
Main Authors: Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum Zaki, Kwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Journal of Experimental & Clinical Cancer Research
Online Access:https://doi.org/10.1186/s13046-023-02668-3
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1186/s13046-023-02668-3

Similar Items

  • First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
    by: Christopher B. Cole, et al.
    Published: (2023-03-01)
  • 879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
    by: Massimo Fantini, et al.
    Published: (2023-11-01)
  • Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
    by: Massimo Fantini, et al.
    Published: (2018-01-01)
  • Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells
    by: Massimo Fantini, et al.
    Published: (2024-12-01)
  • Glycans as biomarkers: Status and perspectives
    by: Janković Miroslava
    Published: (2011-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs